Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrea Forschner

Showing results (61-70 of 157) with videos related to

Pageof 16
Sort By:
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|June 17, 2022
Zirkulierende Tumor-DNA (ctDNA) bei der Entdeckung von Rezidiven bei Melanompatienten mit adjuvanter Anti-PD-1-TherapieAndrea Forschner, Heike Niessner, Tobias Sinnberg, et al.
Cancers|May 2, 2020
Are Pathogenic Germline Variants in Metastatic Melanoma Associated with Resistance to Combined Immunotherapy?Teresa Amaral, Martin Schulze, Tobias Sinnberg, et al.
Melanoma Research|May 5, 2011
Sex differences in survival of cutaneous melanoma are age dependent: an analysis of 7338 patientsLiljana Mervic, Ulrike Leiter, Friedegund Meier, et al.
Diagnostics (Basel, Switzerland)|June 10, 2023
Whole-Body Magnetic Resonance Imaging (MRI) for Staging Melanoma Patients in Direct Comparison to Computed Tomography (CT): Results from a Prospective Positron Emission Tomography (PET)/CT and PET/MRI StudyChristian Philipp Reinert, Cecilia Liang, Matthias Weissinger, et al.
Targeted Oncology|February 8, 2021
Serum S100B and LDH at Baseline and During Therapy Predict the Outcome of Metastatic Melanoma Patients Treated with BRAF InhibitorsMaximilian Gassenmaier, Max M Lenders, Andrea Forschner, et al.
European Journal of Nuclear Medicine and Molecular Imaging|August 24, 2017
18F-FDG-PET detects complete response to PD1-therapy in melanoma patients two weeks after therapy startFerdinand Seith, Andrea Forschner, Holger Schmidt, et al.
Diagnostics (Basel, Switzerland)|August 10, 2024
An Automated Real-Time PCR Assay versus Next-Generation Sequencing in the Detection of <i>BRAF</i> V600 Mutations in Melanoma Tissue SamplesDaniela Lenders, Irina Bonzheim, Matthias Hahn, et al.
Oncotargets and Therapy|June 26, 2020
Circulating Tumor DNA Correlates with Outcome in Metastatic Melanoma Treated by BRAF and MEK Inhibitors - Results of a Prospective Biomarker StudyAndrea Forschner, Stephanie Weißgraeber, Dirk Hadaschik, et al.
Acta Radiologica (Stockholm, Sweden : 1987)|May 26, 2021
Efficacy and tolerability of chemosaturation in patients with hepatic metastases from uveal melanomaArne Estler, Christoph Artzner, Michael Bitzer, et al.
European Journal of Nuclear Medicine and Molecular Imaging|March 4, 2020
Influence of <sup>18</sup>F-FDG PET/CT on clinical management and outcome in patients with advanced melanoma not primarily selected for surgery based on a linked evidence approachSusann-Cathrin Olthof, Andrea Forschner, Peter Martus, et al.
Pageof 16

Showing results (61-70 of 157) with videos related to

Sort By:
Pageof 16
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|June 17, 2022
Zirkulierende Tumor-DNA (ctDNA) bei der Entdeckung von Rezidiven bei Melanompatienten mit adjuvanter Anti-PD-1-TherapieAndrea Forschner, Heike Niessner, Tobias Sinnberg, et al.
Cancers|May 2, 2020
Are Pathogenic Germline Variants in Metastatic Melanoma Associated with Resistance to Combined Immunotherapy?Teresa Amaral, Martin Schulze, Tobias Sinnberg, et al.
Melanoma Research|May 5, 2011
Sex differences in survival of cutaneous melanoma are age dependent: an analysis of 7338 patientsLiljana Mervic, Ulrike Leiter, Friedegund Meier, et al.
Diagnostics (Basel, Switzerland)|June 10, 2023
Whole-Body Magnetic Resonance Imaging (MRI) for Staging Melanoma Patients in Direct Comparison to Computed Tomography (CT): Results from a Prospective Positron Emission Tomography (PET)/CT and PET/MRI StudyChristian Philipp Reinert, Cecilia Liang, Matthias Weissinger, et al.
Targeted Oncology|February 8, 2021
Serum S100B and LDH at Baseline and During Therapy Predict the Outcome of Metastatic Melanoma Patients Treated with BRAF InhibitorsMaximilian Gassenmaier, Max M Lenders, Andrea Forschner, et al.
European Journal of Nuclear Medicine and Molecular Imaging|August 24, 2017
18F-FDG-PET detects complete response to PD1-therapy in melanoma patients two weeks after therapy startFerdinand Seith, Andrea Forschner, Holger Schmidt, et al.
Diagnostics (Basel, Switzerland)|August 10, 2024
An Automated Real-Time PCR Assay versus Next-Generation Sequencing in the Detection of <i>BRAF</i> V600 Mutations in Melanoma Tissue SamplesDaniela Lenders, Irina Bonzheim, Matthias Hahn, et al.
Oncotargets and Therapy|June 26, 2020
Circulating Tumor DNA Correlates with Outcome in Metastatic Melanoma Treated by BRAF and MEK Inhibitors - Results of a Prospective Biomarker StudyAndrea Forschner, Stephanie Weißgraeber, Dirk Hadaschik, et al.
Acta Radiologica (Stockholm, Sweden : 1987)|May 26, 2021
Efficacy and tolerability of chemosaturation in patients with hepatic metastases from uveal melanomaArne Estler, Christoph Artzner, Michael Bitzer, et al.
European Journal of Nuclear Medicine and Molecular Imaging|March 4, 2020
Influence of <sup>18</sup>F-FDG PET/CT on clinical management and outcome in patients with advanced melanoma not primarily selected for surgery based on a linked evidence approachSusann-Cathrin Olthof, Andrea Forschner, Peter Martus, et al.
Pageof 16